Meeting
2024 ASCO Annual Meeting
Clinical validation of Northstar Select, a novel liquid biopsy assay for comprehensive genomic profiling of solid tumors.
Authors
Xavier Bower
BillionToOne, Inc., Menlo Park, CA
Xavier Bower , Jan Wignall , Joyce Zhu , Michael O'Sullivan , Naomi Searle , Lenny Hong , Matthew Gordon Varga , Jason Luong , Esther Lin , Marie Erica Simon , David Tsao , John ten Bosch , Wen Zhou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 3072)
DOI
10.1200/JCO.2024.42.16_suppl.3072
Abstract #
3072
Poster Bd #
217
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Characterization of diverse targetable ERBB2 alterations in 512,993 patients with solid tumors.
First Author: Dazhi Liu
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Novel potential mechanisms of acquired resistance to anti-EGFR monoclonal antibody (mAb) therapy detected in liquid biopsies (LBx) from patients (pts) with advanced colorectal cancer (CRC).
First Author: Christine Megerdichian Parseghian
Poster
2023 ASCO Annual Meeting
Clinical utility of liquid-based comprehensive genomic profiling (CGP) in gastrointestinal stromal tumors (GIST).
First Author: Lindsey Hildebrand
Poster
2023 ASCO Annual Meeting
Gynecologic-cancer analysis of ARID1A alterations detected in tissue and liquid biopsies.
First Author: Natalie Danziger